Evidence map›Paper›PMID 39247497›Full record

ArticleNeuro-oncology advances

Oligodendroglioma patient survival is associated with circulating B-cells and age.

Jennie W Taylor, Gayathri Warrier, Helen M Hansen, Lucie McCoy, Terri Rice, Geno Guerra, Stephen S Francis, Jennifer L Clarke, Paige M Bracci, Sara Hadad and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jennie W TaylorWeill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-3980-5626
Gayathri WarrierDepartment of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-1764-2571
Helen M HansenDepartment of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Lucie McCoyDepartment of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-2728-6083
Terri RiceDepartment of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Geno GuerraDepartment of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-9870-9998
Stephen S FrancisDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Jennifer L ClarkeWeill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-8054-7342
Paige M BracciDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-9338-9307
Sara HadadDepartment of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Karl T KelseyDepartments of Epidemiology; Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, USA.ORCID https://orcid.org/0000-0002-2302-1600
Margaret WrenschDepartment of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Annette M MolinaroDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
John K WienckeDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
GENETIC EPIDEMIOLOGY OF MALIGNANT GLIOMAR01CA052689 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K., WRENSCH, MARGARET R. · 1991 to 2015
$20.5M
International Case Control Study of Malignant GliomaR01CA139020 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BONDY, MELISSA L. · 2010 to 2015
$16.0M
Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Training in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5M
Discovering Infection-mediated Pathways of Glioma Etiology and Prognosis by Leveraging Multiplex Serology and ImmunogenomicsR01CA266676 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRANCIS, STEPHEN STARKO · 2022 to 2025
$2.6M
Biomarkers of survival in glioma epidemiologyR01CA126831 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2008 to 2013
$2.5M
NCCDPHP CDC HHS NU58DP006344NCI NIH HHS P30 CA082103NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA052689NCI NIH HHS R01 CA126831NCI NIH HHS R01 CA139020NCI NIH HHS R01 CA266676NCI NIH HHS R25 CA112355NCI NIH HHS T32 CA151022NCRR NIH HHS UL1 RR024131
6 · The paper itself

Abstract

Background: Variations in survival among patients with oligodendroglioma are unexplained by known prognostic factors. To assess the impact of peripheral immune profiles on prognosis, we applied immunomethylomics analyses-DNA methylation of archived whole blood samples, to characterize immune cells. Methods: We compared the proportions of immune cells from patients with oligodendroglioma to other glioma subtypes and controls. We used recursive partitioning analysis (RPA) within the oligodendrogliomas to correlate with survival. Results: Patients with oligodendrogliomas (141) were median age at diagnosis of 44 years; 57% male; 75% White; 60% prior chemotherapy; and 25% on dexamethasone at sample collection. Patients with oligodendrogliomas had immune profiles more similar to controls than other glioma subtypes, though with notably lower B-cells. RPA of patients with oligodendrogliomas delineated 2 survival groups based on an interaction between age and B-naïve cells. Patients with longer survival (median 24.2 years) were ≤42 years of age with higher B-naïve cells versus worse survival (median 16.9 years) who were ≤42 years of age with lower B-naïve cells or >42 years of age ( Conclusions: Peripheral blood immune profiles in oligodendroglioma suggested that younger patients with lower B-naïve cells experienced shorter survival. Though our findings lack of validation cohort and use a heterogenous patient population, they suggest peripheral blood immune profiles may be prognostic for patients with glioma and warrant further investigation.

Indexed as

epigeneticsgliomaimmune factorsimmunomethylomicsoligodendroglioma

Identifiers

PMID39247497
PMCPMC11379917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.